2月14日，万泰生物盘中上涨2.13%，截至11:05，报67.1元/股，成交1.1亿元，换手率0.13%，总市值848.9亿元。
资料显示，北京万泰生物药业股份有限公司位于北京市昌平区科学园路31号，公司主要从事生物诊断试剂与疫苗的研发和生产，产品涵盖酶免、胶体金、化学发光、核酸检测、生化、疫苗以及质控品等多个领域。公司拥有数百名不同专业技术人才及多个技术平台，产品销往全球三十多个国家，且在国家历次重大传染病爆发时，如SARS(非典)、H5N1型禽流感、甲型流感、EV71型手足口病等，满足临床及疾病监控需求。
截至9月30日，万泰生物股东户数3.27万，人均流通股3.87万股。
2024年1月-9月，万泰生物实现营业收入19.48亿元，同比减少60.79%；归属净利润2.67亿元，同比减少85.25%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.